VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT

Background & Aims: Contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT) are used to assess the response of hepatocellular carcinoma after transarterial chemoembolization. Our aim was to perform a systematic review to compare CEUS and CECT for therapeutic response assessment to transarterial chemoembolization in the treatment of hepatocellular carcinoma. Method: PubMed, Embase, and the Cochrane Library databases were searched from inception until January 1, 2016. Participants: patients with hepatocellular carcinoma. Intervention: transarterial chemoembolization and CECT vs CEUS. Results. Sixteen studies were included in the systematic review. The total number of patients was 858 and the mean patient age ranged from 42 to 73 years. The mean tumor size ranged from 1.0 cm to 4.3 cm. The sensitivity and specificity of CEUS ranged from 46% to 100% and 65% to 100%, respectively, and that of CECT ranged from 34% to 87% and 92% to 100%, respectively. The accuracy of CEUS ranged from 72.6% to 100% and that of CECT from 61% to 94%. Marked heterogeneity was present among the studies. Conclusion: CEUS is comparable with CECT for the therapeutic response assessment after transarterial chemoembolization. Abbreviations: CECT: Contrast-enhanced CT; CEUS: Contrast-enhanced Ultrasound; CT: Computed Tomography; HCC: Hepatocellular Carcinoma; MDCT: Multidetector row CT; MRI: Magnetic Resonance Imaging; mRECIST: modified Response Evaluation Criteria in Solid Tumors; NPV: Negative Predictive Value; PPV: Positive Predictive Value; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies; RFA: Radiofrequency Ablation; TACE: Transcatheter Arterial Chemoembolization.

Download Full-text

Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.5743 ◽

2010 ◽

Vol 28 (19) ◽

pp. 3154-3159 ◽

Cited By ~ 77

Author(s):

Patrick G. Morris ◽

Colleen Lynch ◽

John N. Feeney ◽

Sujata Patil ◽

Jane Howard ◽

...

Keyword(s):

Breast Cancer ◽

Computed Tomography ◽

Positron Emission Tomography ◽

Metastatic Breast Cancer ◽

Bone Scintigraphy ◽

Metastatic Breast ◽

Emission Tomography ◽

Osseous Metastases ◽

Positron Emission ◽

Pet Ct

Purpose Although the accurate detection of osseous metastases in the evaluation of patients with suspected metastatic breast cancer (MBC) has significant prognostic and therapeutic implications, the ideal diagnostic approach is uncertain. In this retrospective, single-institution study, we compare the diagnostic performance of integrated positron emission tomography/computed tomography (PET/CT) and bone scintigraphy (BSc) in women with suspected MBC. Patients and Methods Women with suspected MBC evaluated with PET/CT and BSc (within 30 days) between January 1, 2003 and June 30, 2008, were identified through institutional databases. Electronic medical records were reviewed, and radiology reports were classified as positive/negative/equivocal for osseous metastases. A nuclear medicine radiologist (blinded to correlative and clinical end points) reviewed all equivocal PET/CT and BSc images and reclassified some reports. Final PET/CT and BSc classifications were compared. Baseline patient/tumor characteristics and bone pathology were recorded and compared to the final imaging results. Results We identified 163 women who had a median age of 52 years (range, 30 to 90 years); 32% had locally advanced breast cancer, 42% had been diagnosed with breast cancer less than 12 weeks before identification. Twenty studies were originally deemed equivocal (five with PET/CT, and 15 with BSc), and 13 (65%) of these studies were reclassified after radiology review. Overall, PET/CT and BSc were highly concordant for reporting osseous metastases with 132 paired studies (81%); 32 (20%) were positive, and 100 (61%) were negative. Thirty-one occurrences (19%) were discordant. Twelve of these (39%) had pathology confirming osseous metastases: nine (of 18) were PET/CT positive and BSc negative; one (of three) was PET/CT positive and BSc equivocal; and two (of two) were PET/CT equivocal and BSc negative. Conclusion This study supports the use of PET/CT in detecting osseous metastases for suspected MBC. Whether PET/CT may supplant BSc in this setting is unknown.

Download Full-text

Bilateral femoral head osteonecrosis in a patient with metastatic breast cancer receiving long‑term zoledronic acid treatment: A case report

Molecular and Clinical Oncology ◽

10.3892/mco.2021.2328 ◽

2021 ◽

Vol 15 (2) ◽

Author(s):

Kazuo Matsuura ◽

Toshiaki Saeki ◽

Takao Takahashi ◽

Tomoaki Torigoe ◽

Keisuke Watarai ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Case Report ◽

Zoledronic Acid ◽

Femoral Head ◽

Acid Treatment ◽

Metastatic Breast ◽

Femoral Head Osteonecrosis

Download Full-text

Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.630 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 630-630

Author(s):

J. De la Haba ◽

A. Rodriguez-Lescure ◽

J. M. Baena ◽

J. Martin Liberal ◽

S. Morales ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Zoledronic Acid ◽

Cancer Patients ◽

Acid Treatment ◽

Metastatic Breast ◽

Final Analysis ◽

Breast Cancer Patients

Download Full-text

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta

Bone Abstracts ◽

10.1530/boneabs.4.oc8 ◽

2015 ◽

Author(s):

Craig Munns ◽

Lauren Peacock ◽

Kathy Mikulec ◽

Michaela Kneissel ◽

Ina Kramer ◽

...

Keyword(s):

Zoledronic Acid ◽

Mouse Model ◽

Osteogenesis Imperfecta ◽

Acid Treatment ◽

Sclerostin Antibody

Download Full-text

Monitoring Therapeutic Response of Metastatic Breast Lesions Using Magnetic Resonance Imaging of Water Self-Diffusion Coefficients

10.21236/ada421349 ◽

2003 ◽

Author(s):

Douglas J. Ballon

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Diffusion Coefficients ◽

Therapeutic Response ◽

Metastatic Breast ◽

Breast Lesions ◽

Resonance Imaging ◽

Self Diffusion

Download Full-text

Prognostic Role of Hedgehog-GLI1 Signaling Pathway in Aggressive and Metastatic Breast Cancers

Current Drug Metabolism ◽

10.2174/1389200221666200122120625 ◽

2020 ◽

Vol 21 (1) ◽

pp. 33-43 ◽

Cited By ~ 1

Author(s):

Prasuja Rokkam ◽

Shailender Gugalavath ◽

Deepak Kakara Gift Kumar ◽

Rahul Kumar Vempati ◽

Rama Rao Malla

Keyword(s):

Breast Cancer ◽

Signaling Pathway ◽

Neural Development ◽

Splice Variants ◽

Metastatic Breast ◽

Basic Function ◽

Breast Cancers ◽

Breast Cancer Patients ◽

Aberrant Expression ◽

Cellular Processes

Glioma-associated oncogene homolog 1 (GLI1) is reported as an amplified gene in human glioblastoma cells. It is a krupple like transcription factor, belonging to the zinc finger family. The basic function of GLI1 is normal neural development at various stages of human. The GLI1 gene was first mapped on the chromosome sub-bands 12q13.3-14.1. Further, single nucleotide polymorphism is mostly observed in translating a region of 5’ and 3’- UTR of GLI1 gene in addition to two post-transcriptional splice variants, GLIΔN and tGLI. Additionally, it also regulates a plethora of gene which mediates crucial cellular processes like proliferation, differentiation, oncogenesis, EMT, and metastasis. It also regulates tumor tolerance, chemoresistance, and radioresistance. Aberrant expression of GLI1 predicts the poor survival of breast cancer patients. GLI1 is an essential mediator of the SHH signaling pathway regulating self-renewal of stem cells, angiogenesis, and expression of FOXS1, CYR61. GLI1 mediated HH pathway can induce apoptosis. Hence, GLI1 can be a future diagnostic, prognostic marker, and as well as a potent target of therapeutics in breast cancer.

Download Full-text